Free Trial
NASDAQ:NXTC

NextCure (NXTC) Stock Price, News & Analysis

NextCure logo
$1.34 -0.07 (-4.96%)
(As of 04:15 PM ET)

About NextCure Stock (NASDAQ:NXTC)

Key Stats

Today's Range
$1.32
$1.43
50-Day Range
$1.27
$1.54
52-Week Range
$1.03
$2.57
Volume
29,339 shs
Average Volume
122,369 shs
Market Capitalization
$37.53 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00
Consensus Rating
Buy

Company Overview

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

NextCure Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
91st Percentile Overall Score

NXTC MarketRank™: 

NextCure scored higher than 91% of companies evaluated by MarketBeat, and ranked 107th out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    NextCure has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    NextCure has only been the subject of 1 research reports in the past 90 days.

  • Read more about NextCure's stock forecast and price target.
  • Earnings Growth

    Earnings for NextCure are expected to grow in the coming year, from ($1.87) to ($1.44) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of NextCure is -0.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of NextCure is -0.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    NextCure has a P/B Ratio of 0.50. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about NextCure's valuation and earnings.
  • Percentage of Shares Shorted

    0.31% of the float of NextCure has been sold short.
  • Short Interest Ratio / Days to Cover

    NextCure has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in NextCure has recently decreased by 10.43%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    NextCure does not currently pay a dividend.

  • Dividend Growth

    NextCure does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.31% of the float of NextCure has been sold short.
  • Short Interest Ratio / Days to Cover

    NextCure has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in NextCure has recently decreased by 10.43%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    NextCure has a news sentiment score of -0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for NextCure this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, NextCure insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    13.30% of the stock of NextCure is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    42.65% of the stock of NextCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about NextCure's insider trading history.
Receive NXTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NextCure and its competitors with MarketBeat's FREE daily newsletter.

NXTC Stock News Headlines

NextCure Reports Improved Financial Performance and Strategic Focus
NextCure’s Strategic Shift and Financial Stability Drive Buy Rating
Has Trump Finally Gone Too Far?
Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.
NextCure reports data from LNCB74, NC410 studies
NextCure (NXTC) Earnings Dates & Reports
See More Headlines

NXTC Stock Analysis - Frequently Asked Questions

NextCure's stock was trading at $1.14 at the start of the year. Since then, NXTC stock has increased by 17.5% and is now trading at $1.34.
View the best growth stocks for 2024 here
.

NextCure, Inc. (NASDAQ:NXTC) issued its earnings results on Thursday, August, 1st. The company reported ($0.55) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by $0.19.

NextCure (NXTC) raised $75 million in an initial public offering (IPO) on Thursday, May 9th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofAMerrill Lynch, Pierce and Piper Jaffray acted as the underwriters for the IPO.

NextCure's top institutional investors include Assenagon Asset Management S.A. (0.30%).
View institutional ownership trends
.

Shares of NXTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that NextCure investors own include Waste Connections (WCN), DiamondRock Hospitality (DRH), The RMR Group (RMR), AUO (AUOTY), American Water Works (AWK), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR).

Company Calendar

Last Earnings
8/01/2024
Today
11/14/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
3/20/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:NXTC
Fax
N/A
Employees
90
Year Founded
2015

Price Target and Rating

Average Stock Price Target
$4.00
High Stock Price Target
$4.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+198.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-62,720,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.70 per share

Miscellaneous

Free Float
24,282,000
Market Cap
$37.53 million
Optionable
Optionable
Beta
0.80
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:NXTC) was last updated on 11/14/2024 by MarketBeat.com Staff
From Our Partners